CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
pharmaphorum
NOVEMBER 2, 2022
Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other respiratory pathogens, including those that may cause future pandemics. For example, Sanofi paid $3.2
Let's personalize your content